Elvina Almuradova, Associate Professor of Oncology at the European Institute of Oncology, shared a post on LinkedIn about a paper he co-authored with colleagues published in Cancer Treatment Reviews:
“Proud of our team’s work!
Our meta-analysis confirms that HER2 IHC 3+ disease is biologically and clinically distinct, with >2-fold higher pCR vs HER2 2+/ISH+.
Quantitative HER2 assessment should no longer be ignored in neoadjuvant planning.”
Title: Comparison of the pathological complete response between immunohistochemistry HER2 (3 + ) and HER2 (2 + )/ISH + Early-stage breast cancer: a systematic review and meta-analysis
Authors: Kadriye Bir Yucel, Yusuf Ilhan, Elvina Almuradova, Murat Bardakci, Cigdem Dinckal, Yakup Ergun
You can read the full article in Cancer Treatment Reviews.
More from Elvina Almuradova on OncoDaily.